Literature DB >> 8167481

BCG vaccine in superficial bladder cancer.

N Sharma, S Prescott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8167481      PMCID： PMC2539986          DOI： 10.1136/bmj.308.6932.801

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  13 in total

Review 1.  BCG treatment of superficial transitional cell carcinoma.

Authors:  P F Schellhammer
Journal:  Urology       Date:  1991       Impact factor: 2.649

Review 2.  The pT1 G3 bladder tumour.

Authors:  B R Birch; S J Harland
Journal:  Br J Urol       Date:  1989-08

3.  Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer.

Authors:  H W Herr; V P Laudone; R A Badalament; H F Oettgen; P C Sogani; B D Freedman; M R Melamed; W F Whitmore
Journal:  J Clin Oncol       Date:  1988-09       Impact factor: 44.544

4.  The plight of the patient with carcinoma in situ of the bladder.

Authors:  D C Utz; K A Hanash; G M Farrow
Journal:  J Urol       Date:  1970-02       Impact factor: 7.450

5.  Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patients who have failed thiotepa and/or mitomycin C.

Authors:  M S Soloway; A Perry
Journal:  J Urol       Date:  1987-05       Impact factor: 7.450

6.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

7.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

8.  Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.

Authors:  W J Catalona; M A Hudson; D P Gillen; G L Andriole; T L Ratliff
Journal:  J Urol       Date:  1987-02       Impact factor: 7.450

9.  Requirement of a thymus dependent immune response for BCG-mediated antitumor activity.

Authors:  T L Ratliff; D Gillen; W J Catalona
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

Review 10.  Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.

Authors:  M S Cookson; M F Sarosdy
Journal:  J Urol       Date:  1992-09       Impact factor: 7.450
View more
  2 in total

1.  Arthritis as a complication of intravesical BCG vaccine.

Authors:  M Devlin; A Deodhar; M Davis
Journal:  BMJ       Date:  1994-06-18

Review 2.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.